To analyze the application value of da Vinci robot-assisted pelvic dissection in the treatment of some patients with advanced and recurrent cancer in gynecology.

19 patients who received robot-assisted PE from the first medical center of the PLA General Hospital from Sep. 2014 to Dec. 2021 were selected as the study subjects. Analyze the general material of the cases, the relevant indicators in the perioperative period and the follow-up data. At the same time, review the literature and share relevant experience.

Among 19 cases of da Vinci robot-assisted PE, 21.05% were initially treated and 78.95% were relapsed. 17 patients received robotic MDT cooperative surgery, 70.59% of which were combined with two departments and 29.41% with three departments. The resection rate of R0 was 89.47%, the rate of neoadjuvant chemotherapy was 52.63%, and the rate of serious complications was 10.53%. Compared with different types of robot-assisted PE, anterior pelvic PE accounted for 52.63%, posterior pelvic PE accounted for 31.58%, and total pelvic PE accounted for 15.79%. There was no significant difference in average operation time, maximum diameter of tumor resection, blood transfusion rate, R0 resection rate and conversion rate among the three groups (P>0.05). The total pelvic PE group had the most surgical bleeding, the posterior pelvic PE group was slightly inferior, and the anterior pelvic PE group had the least [(700±444.41) mL vs (375±271.57) mL vs (147±86.16) mL, P=0.019]. The average postoperative hospital stay in the anteriorr pelvic PE group was less than that in the total pelvic PE group [(13.80±5.71) days vs (22.33±5.13) days, P=0.046]. The average follow-up time of all patients was (33.05±25.73) months, and the median follow-up time was 23 months; One-year and two-year OS were 84.21% and 63.16% respectively.

Da Vinci robot-assisted pelvic dissection has a definite effect on the treatment of some patients with advanced and recurrent cancer in gynecology. Reasonable control of surgical indications, high-level robotic surgical MDT team, scientific perioperative management, and individualized comprehensive treatment plan can benefit more patients.